Table 3 Demographic and medical data.
Population | ||
|---|---|---|
Variable | Efficacy + safety | HRQoL a |
Number of patients enrolled, N | 82 | 48 b |
Number of evaluable patients, N (%) | 82 (100%) | 30 (100%) |
Sex, n (%) | ||
Male | 34 (41%) | 19 (63%) |
Female | 46 (56%) | 11 (37%) |
Missing | 2 (2%) | 0 |
Age (years), mean (range) | 34 (1-74) | 30 (3-74) |
Age group, n (%) | ||
< 14 years | 17 (21%) | 11 (37%) |
≥ 14 years | 65 (79%) | 19 (63%) |
Diagnosis, n (%) | ||
Common variable immunodeficiency | 44 (54%) | 11 (37%) |
X-linked agammaglobulinaemia (Bruton disease) | 13 (16%) | 9 (30%) |
Severe combined immunodeficiency | 4 (5%) | 1 (3%) |
IgG subclass deficiency | 4 (5%) | 1 (3%) |
Other congenital hypo- or agammaglobulinaemia | 5 (6%) | 2 (7%) |
Secondary immunodeficiency | 9 (11%) | 5 (17%) |
Missing | 3 (4%) | 1 (3%) |
Prior treatment with immunoglobulins, n (%) | ||
Intravenous infusions | 60 (73%) | 30 (100%) |
Intramuscular infusions | 3 (4%) | 0 |
Subcutaneous infusions | 12 (15%) | 0 |
None | 6 (7%) | 0 |
Missing | 1 (1%) | 0 |